Exact Sciences Corporation
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Exact Sciences Corporation develops and markets molecular diagnostic tests focused on cancer prevention, early detection, screening, surveillance, treatment guidance, monitoring, and therapy selection. Founded in 1995 and headquartered in Madison, Wisconsin, the company operates primarily in the United States with select products available in over 90 countries, serving patients, healthcare providers, health systems, and researchers through its state-of-the-art laboratories. Its core products and services include Cologuard and Cologuard Plus, noninvasive stool-based DNA screening tests for colorectal cancer in adults aged 45 and older at average risk; Cancerguard, a multi-cancer early detection blood test designed to identify multiple cancers in earlier stages; Oncoguard Liver, a blood-based surveillance test for hepatocellular carcinoma in individuals with cirrhosis or chronic hepatitis B; Riskguard, a blood, cheek swab, or saliva test assessing hereditary cancer risk for breast, colorectal, endocrine, endometrial, gastric, kidney, ovarian, pancreatic, prostate, and skin cancers; Oncotype DX Breast Recurrence Score and Oncotype DX Breast DCIS Score, genomic tests evaluating recurrence risk in early-stage breast cancer to guide treatment decisions and avoid overtreatment; Oncotype DX Colon Recurrence Score, a genome-based test quantifying recurrence risk in stage II/III colon cancers; OncoExTra, a solid tumor profiling test aiding therapy selection for advanced, metastatic, refractory, relapsed, or recurrent solid tumors; and pipeline developments such as a colorectal cancer screening blood test, Oncoliquid for advanced cancer therapy guidance, and additional tests for esophageal, breast, lung, liver, and pancreatic cancers. In November 2025, Abbott Laboratories agreed to acquire Exact Sciences for approximately $21 billion to $23 billion including debt, at $105 per share, marking a major strategic transaction expected to close in the second quarter of 2026 subject to shareholder and regulatory approvals; this deal incorporates Exact Sciences' portfolio, including Cologuard and Oncotype DX, into Abbott's diagnostics offerings to expand cancer screening access and boost annual diagnostics revenue beyond $12 billion. Earlier developments include the 2024 launch of Riskguard through subsidiary PreventionGenetics, the 2022 introduction of Oncoguard Liver, and an August 2025 exclusive licensing agreement with Freenome for current and future blood-based colorectal cancer screening tests. The company previously acquired Genomic Health in 2018 and Paradigm Diagnostics in 2019 to broaden its precision oncology capabilities beyond colorectal cancer.
Abbott Labs shares fall as earnings beat offset by Exact Sciences acquisition drag
96,685 Shares in Exact Sciences Corporation $EXAS Purchased by Capricorn Fund Managers Ltd
Exact Sciences Corporation $EXAS Shares Sold by Exchange Traded Concepts LLC
FNY Investment Advisers LLC Buys Shares of 28,500 Exact Sciences Corporation $EXAS
Banque Pictet & Cie SA Lowers Position in Exact Sciences Corporation $EXAS
Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026
Bridgefront Capital LLC Buys Shares of 11,994 Exact Sciences Corporation $EXAS
ArrowMark Colorado Holdings LLC Purchases 113,603 Shares of Exact Sciences Corporation $EXAS
Exact Sciences Corporation $EXAS Shares Bought by Dimensional Fund Advisors LP
Exact Sciences (EXAS) is a Top-Ranked Momentum Stock: Should You Buy?
CSLLY or EXAS: Which Is the Better Value Stock Right Now?
Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year
Marking National Colorectal Cancer Awareness Month, Privia Health Program Achieves 84% Colorectal Cancer Screening Rate Through Industry Collaboration
DNB Asset Management AS Raises Position in Exact Sciences Corporation $EXAS
Exact Sciences Stockholders Approve Acquisition by Abbott
Here's Why Exact Sciences (EXAS) is a Strong Momentum Stock
Exact Sciences Q4 Earnings Match Estimates, Revenues Beat, Stock Up
Aberdeen Group plc Increases Stock Position in Exact Sciences Corporation $EXAS
Paul Tudor Jones Makes Significant Moves with iShares Core S&P 500 ETF
CSLLY vs. EXAS: Which Stock Is the Better Value Option?